Pfizer Discontinues Cancer Drug: Biotech’s Recently Missed Targets

Pfizer said it is discontinuing its late-stage study of the cancer drug figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer because the study met predefined boundaries for early termination.
Seeking Alpha